Bietti crystalline corneoretinal dystrophy is caused by mutations in the novel gene CYP4V2 - PubMed (original) (raw)
doi: 10.1086/383228. Epub 2004 Mar 23.
Xiaodong Jiao, Francis L Munier, Daniel F Schorderet, Wenliang Yao, Fumino Iwata, Mutsuko Hayakawa, Atsushi Kanai, Muh Shy Chen, Richard Alan Lewis, John Heckenlively, Richard G Weleber, Elias I Traboulsi, Qingjiong Zhang, Xueshan Xiao, Muriel Kaiser-Kupfer, Yuri V Sergeev, J Fielding Hejtmancik
Affiliations
- PMID: 15042513
- PMCID: PMC1181977
- DOI: 10.1086/383228
Bietti crystalline corneoretinal dystrophy is caused by mutations in the novel gene CYP4V2
Anren Li et al. Am J Hum Genet. 2004 May.
Abstract
Bietti crystalline corneoretinal dystrophy (BCD) is an autosomal recessive retinal dystrophy characterized by multiple glistening intraretinal crystals scattered over the fundus, a characteristic degeneration of the retina, and sclerosis of the choroidal vessels, ultimately resulting in progressive night blindness and constriction of the visual field. The BCD region of chromosome 4q35.1 was refined to an interval flanked centromerically by D4S2924 by linkage and haplotype analysis; mutations were found in the novel CYP450 family member CYP4V2 in 23 of 25 unrelated patients with BCD tested. The CYP4V2 gene, transcribed from 11 exons spanning 19 kb, is expressed widely. Homology to other CYP450 proteins suggests that CYP4V2 may have a role in fatty acid and steroid metabolism, consistent with biochemical studies of patients with BCD.
Figures
Figure B1
Alignment of CYP4V2 with CYP450 family members. Mus musculus CYP4V3 shows the highest identify, whereas rabbit CYP2C5 and Bacillus mesenterium CYPBM3, whose structures have been determined crystallographically, are further removed. CYPBM3 was used to model the high-homology area surrounding the active site, and CYP2C5 was used to model the amino-terminal regions for which homology to CYPBM3 was low.
Figure 1
Pedigrees of selected families with BCD with haplotypes of markers in the BCD region. Family 33001 was used in the genomewide scan. Recombinants in individual 4 of family 33010 and individual 6 of family 33011 set the centromeric boundary at D4S2924, as does the lack of homozygosity in D4S3047, D4S3032, and D4S2924 in individual 3 of consanguineous family 33005.
Figure 2
A, Physical map of BCD region at 4q35.1. The BCD region is covered contiguously by 6 overlapping YACs and 32 BACs, representing the shortest path. The STS marker positions are from the NCBI database. B, CYP4V2 cDNAs. Five overlapping cDNA fragments obtained by direct PCR and 5′ and 3′ RACE from human retinal cDNA and RPE cDNA provide a 2,041-bp cDNA. Sequence homology searches show partial sequence overlap with three NCBI predicted cDNA sequences: XM209611, XM114391, and XM209612. C, CYP4V2 gene structure. CYP4V2 gene structure is assembled by alignment of the cDNA sequence to genomic DNA sequence. The 11 identified exons are flanked by recognizable splice sites. The coding region extends as one ORF from the first Met (ATG) codon in exon 1 to the stop (TAA) codon in exon 11. This novel gene consists of 11 exons and spans 19 kb. Thirteen mutations of the CYP4V2 gene found in 23 of 25 unrelated patients with BCD are indicated below the gene structure.
Figure 3
Structure of CYP4V2 protein and selected mutations. A, CYP4V2 protein structure. α Helices are shown as red cylinders, β sheets are shown as yellow ribbons, and the porphyrin ring is shown in blue. B, The peptide preserved by G134X, which truncates the protein just within the main globular domain, is shown in red, and truncated sequences are shown in blue, with the exception of exon 7, which is shown in green. C, The 15-bp deletion, including the 3′ (acceptor) splice site for exon 7, which removes the G, H, and part of the central I helices (green) and their connecting loops and causes uncoiling and displacement of the central I helix (the normal position is shown in light blue, and the displaced position is shown in dark blue). D, Replacement of hydrophobic aromatic tryptophan near or in the transmembrane segment with positively charged arginine (W44R). E, R508H, which might influence heme coordination. F, H331P, predicted to disrupt the I helix. G, I111T, near the surface of the molecule. H, S341P, predicted to disrupt the I helix.
Figure 4
Expression pattern of CYP4V2. PCR was performed with cDNA from various tissues, using primers from exons 5 and 11. The lymphocyte (“ptnt”) sample is from patient 4 in family 33002 and displays a 727-bp fragment lacking exon 7. The negative control is H2O, and the positive control is pooled cDNA from human tissues (Universal cDNA pool [Clontech]).
Similar articles
- Genetic linkage of Bietti crystallin corneoretinal dystrophy to chromosome 4q35.
Jiao X, Munier FL, Iwata F, Hayakawa M, Kanai A, Lee J, Schorderet DF, Chen MS, Kaiser-Kupfer M, Hejtmancik JF. Jiao X, et al. Am J Hum Genet. 2000 Nov;67(5):1309-13. doi: 10.1016/S0002-9297(07)62960-7. Epub 2000 Sep 21. Am J Hum Genet. 2000. PMID: 11001583 Free PMC article. - Recessive mutations in the CYP4V2 gene in East Asian and Middle Eastern patients with Bietti crystalline corneoretinal dystrophy.
Lin J, Nishiguchi KM, Nakamura M, Dryja TP, Berson EL, Miyake Y. Lin J, et al. J Med Genet. 2005 Jun;42(6):e38. doi: 10.1136/jmg.2004.029066. J Med Genet. 2005. PMID: 15937078 Free PMC article. - Novel mutations in the CYP4V2 gene associated with Bietti crystalline corneoretinal dystrophy.
Shan M, Dong B, Zhao X, Wang J, Li G, Yang Y, Li Y. Shan M, et al. Mol Vis. 2005 Sep 12;11:738-43. Mol Vis. 2005. PMID: 16179904 - [Progress in the studies of molecular genetics in Bietti crystalline corneoretinal dystrophy].
Xu F, Sui RF, Dong FT. Xu F, et al. Zhonghua Yan Ke Za Zhi. 2012 Oct;48(10):948-51. Zhonghua Yan Ke Za Zhi. 2012. PMID: 23302251 Review. Chinese. - Bietti Crystalline Dystrophy.
Vargas M, Mitchell A, Yang P, Weleber R. Vargas M, et al. 2012 Apr 12 [updated 2019 Feb 7]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. 2012 Apr 12 [updated 2019 Feb 7]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. PMID: 22497028 Free Books & Documents. Review.
Cited by
- Quickly diagnosing Bietti crystalline dystrophy with deep learning.
Zhang H, Zhang K, Wang J, Yu S, Li Z, Yin S, Zhu J, Wei W. Zhang H, et al. iScience. 2024 Jul 25;27(9):110579. doi: 10.1016/j.isci.2024.110579. eCollection 2024 Sep 20. iScience. 2024. PMID: 39220263 Free PMC article. - Evaluating precision medicine approaches for gene therapy in patient-specific cellular models of Bietti crystalline dystrophy.
Li Y, Yang RR, Li YS, Hsu CW, Jenny LA, Kong Y, Ruan MZ, Sparrow JR, Tsang SH. Li Y, et al. JCI Insight. 2024 Aug 22;9(16):e177231. doi: 10.1172/jci.insight.177231. JCI Insight. 2024. PMID: 39171529 Free PMC article. - DISCREPANCY BETWEEN FUNDUS AUTOFLUORESCENCE ABNORMALITY AND VISUAL FIELD LOSS IN BIETTI CRYSTALLINE DYSTROPHY.
Sakai D, Maeda T, Maeda A, Yamamoto M, Yokota S, Hirami Y, Nakamura M, Takahashi M, Mandai M, Kurimoto Y. Sakai D, et al. Retina. 2024 Aug 1;44(8):1394-1402. doi: 10.1097/IAE.0000000000004114. Retina. 2024. PMID: 39047130 Free PMC article. - In vivo genome editing via CRISPR/Cas9-mediated homology-independent targeted integration for Bietti crystalline corneoretinal dystrophy treatment.
Meng X, Jia R, Zhao X, Zhang F, Chen S, Yu S, Liu X, Dou H, Feng X, Zhang J, Wang N, Xu B, Yang L. Meng X, et al. Nat Commun. 2024 May 6;15(1):3773. doi: 10.1038/s41467-024-48092-9. Nat Commun. 2024. PMID: 38710738 Free PMC article. - Gene replacement therapy in Bietti crystalline corneoretinal dystrophy: an open-label, single-arm, exploratory trial.
Wang J, Zhang J, Yu S, Li H, Chen S, Luo J, Wang H, Guan Y, Zhang H, Yin S, Wang H, Li H, Liu J, Zhu J, Yang Q, Sha Y, Zhang C, Yang Y, Yang X, Zhang X, Zhao X, Wang L, Yang L, Wei W. Wang J, et al. Signal Transduct Target Ther. 2024 Apr 24;9(1):95. doi: 10.1038/s41392-024-01806-3. Signal Transduct Target Ther. 2024. PMID: 38653979 Free PMC article. Clinical Trial.
References
Electronic-Database Information
- Bioccelerator at European Molecular Biology Laboratory, http://eta.embl-heidelberg.de:8000/
- Cytochrome P450 Homepage, http://drnelson.utmem.edu/cytochromep450.html
- Delila Program, Laboratory of Computational and Experimental Biology, National Cancer Institute, National Institutes of Health, http://www.lecb.ncifcrf.gov/~toms/delila.html
- myScience, http://myscience.appliedbiosystems.com/
- National Center for Biotechnology Information, http://www.ncbi.nlm.nih.gov/
References
- Abola E, Bernstein FC, Bryant SH, Koetzle TF, Weng J (1987) Protein data bank. In: Allen FH, Bergerhoff G, Sievers R (eds) Crystallographic databases: information content, software systems, scientific applications. Data Commission of the International Union of Crystallography, Cambridge, pp 107–132
- Ayyagari R, Nestorowicz A, Li Y, Chandrasekharappa S, Chinault C, van Tuinen P, Smith RJH, Hejtmancik JF, Permutt MA (1996) Construction of a YAC contig encompassing the Usher syndrome type 1C and familial hyperinsulinism loci on chromosome 11p14-15.1. Genome Res 6:504–514 - PubMed
- Bietti G (1937) Ueber familiaeres vorkommen von “retinitis punctata albescens” (verbunden mit “dystrophia marginalis cristallinea corneae”), glitzern des glaskoerpers und anderen degenerativen augenveraenderungen. Klin Mbl Augenheilk 99:737–757
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases